Wall Street analysts forecast that Apricus Biosciences, Inc (NASDAQ:APRI) will report earnings of ($0.13) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Apricus Biosciences’ earnings. Apricus Biosciences posted earnings of ($0.04) per share in the same quarter last year, which would suggest a negative year over year growth rate of 225%. The firm is scheduled to issue its next earnings report on Monday, March 12th.

According to Zacks, analysts expect that Apricus Biosciences will report full year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.92) to ($0.28). For the next financial year, analysts expect that the firm will post earnings of $1.28 per share. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Apricus Biosciences.

Apricus Biosciences (NASDAQ:APRI) last released its quarterly earnings results on Thursday, November 2nd. The company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.15). During the same period last year, the company posted ($0.19) earnings per share.

Several research analysts have issued reports on the company. Zacks Investment Research downgraded Apricus Biosciences from a “hold” rating to a “sell” rating in a report on Friday, August 4th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Apricus Biosciences in a report on Wednesday, August 30th.

Apricus Biosciences (NASDAQ:APRI) traded up $0.01 during midday trading on Tuesday, reaching $1.59. The company had a trading volume of 73,700 shares, compared to its average volume of 677,215. Apricus Biosciences has a 1-year low of $0.86 and a 1-year high of $4.07.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Apricus Biosciences, Inc (APRI) to Post -$0.13 Earnings Per Share” was posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/14/zacks-analysts-expect-apricus-biosciences-inc-apri-to-post-0-13-earnings-per-share.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Get a free copy of the Zacks research report on Apricus Biosciences (APRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.